Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allakos Inc.
  6. News
  7. Summary
    ALLK   US01671P1003

ALLAKOS INC.

(ALLK)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-08 pm EST
6.880 USD   -5.62%
2022Allakos Inc.(NasdaqGS:ALLK) added to S&P Biotechnology Select Industry Index
CI
2022Allakos Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALLAKOS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

04/20/2022 | 04:05pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 15, 2022, Mark Asbury informed Allakos Inc. (the "Company") of his decision to retire from his position as Chief Legal Officer and General Counsel of the Company effective April 19, 2022 and agreed to assist the Company in making an orderly transition of Mr. Asbury's responsibilities by remaining an employee through June 30, 2022. Meg Fitzgerald has been appointed as the Company's Senior Vice President, General Counsel, Secretary and Chief Compliance Officer effective April 19, 2022.

On April 17, 2022, in connection with Mr. Asbury's departure, he and the Company entered into a Separation Agreement (the "Separation Agreement") setting forth the terms of the separation. Among other matters, the Separation Agreement provides for the Company to pay Mr. Asbury a lump sum cash payment in the amount of $552,590.82, inclusive of nine months of COBRA premiums. The Separation Agreement contains a customary release of claims.

The Separation Agreement becomes effective on the eighth day following its execution provided that neither party has exercised its right to revoke such agreement in accordance with its terms.

The foregoing description of the Separation Agreement does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits

Exhibit
Number                                  Description

            Separation Agreement, dated April 17, 2022, by and between Mark Asbury
  10.1    and Allakos Inc.

          Cover Page Interactive Data File (embedded within the Inline XBRL
  104     document)



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ALLAKOS INC.
2022Allakos Inc.(NasdaqGS:ALLK) added to S&P Biotechnology Select Indu..
CI
2022Allakos Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications..
GL
2022Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications..
AQ
2022Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Soc..
AQ
2022Allakos Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Soc..
GL
2022Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Soc..
AQ
2022ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
More news
Analyst Recommendations on ALLAKOS INC.
More recommendations